Gold(I) complexes and gold(I) dithiocarbamate polymers as anticancer therapeutics. The Au(I) ion within the gold(I) complexes is coordinated to two phosphine ligands. The repeating unit formed by Au(I) ion coordinating to dithiocarbamte ligands are connected by Au(I)Au(I) interactions within the gold(I) dithiocarbamate polymers. Also disclosed are methods of synthesis, pharmaceutical compositions incorporating the gold(I) complexes, pharmaceutical compositions incorporating the gold(I) dithiocarbamate polymers, and methods of treating cancer.

A method of forming compounds that comprise a heterocyclic carbene ligand is provided. In particular, an oxazole or a thioazole carbene are used in place of the traditional imidazole carbene. These compounds may be used in OLEDs to provide devices having improved properties, such as stability and color-tuning.

An organic magnesium phosphide expressed by Formula (1) below and an organic magnesium phosphide complex expressed by Formula (9) below are provided, and a manufacturing method of organic phosphorus compound is characterized in that the above compounds used as a reagent is reacted with an electrophile:

##STR00001##

wherein R.sup.1 and R.sup.2 are each independently an aliphatic group, heteroaliphatic group, alicyclic group, or heterocyclic group, and X is chlorine, bromine, or iodine,

##STR00002##

wherein R.sup.3 and R.sup.4 are each independently an aliphatic group, heteroaliphatic group, aromatic group, alicyclic group, or heterocyclic group, and X and Y are each independently chlorine, bromine, or iodine.

Disclosed are a pincer-type ligand having a structurally rigid acridane structure and a metal complex consisting of the pincer-type ligand and a metal bound to each other, and exhibiting high reactivity and stability during a variety of bonding activation reactions. T-shaped complexes can be prepared from .sup.acriPNP(4,5-bis(diisopropylphosphino)-2,7,9,9-tetramethyl-9H-acrid in-10-ide), which is a pincer-type PNP ligand having an acridane structure, and metal complexes, which can be structurally rigid and thus exhibit excellent reactivity and stability based on minimized structural change thereof, can be prepared by introducing an acridane structure into the backbone thereof. The PNP ligand is structurally stable and has novel chemical properties, as compared to conventional similar ligands, and thus can be utilized in a wide range of catalytic reactions and material chemistry.

Gold(I) complexes and gold(I) dithiocarbamate polymers as anticancer therapeutics. The Au(I) ion within the gold(I) complexes is coordinated to two phosphine ligands. The repeating unit formed by Au(I) ion coordinating to dithiocarbamate ligands are connected by Au(I)-Au(I) interactions within the gold(I) dithiocarbamate polymers. Also disclosed are methods of synthesis, pharmaceutical compositions incorporating the gold(I) complexes, pharmaceutical compositions incorporating the gold(I) dithiocarbamate polymers, and methods of treating cancer.

Vanadium phosphinic complex having general formula (I) or (II):

V(X).sub.3[P(R.sub.1).sub.n(R.sub.2).sub.3-n].sub.2(I)

V(X).sub.3[(R.sub.3).sub.2P(R.sub.4)P(R.sub.3).sub.2](II) wherein: X represents an anion selected from halogens such as, for example, chlorine, bromine, iodine, preferably chlorine; or is selected from the following groups: thiocyanate, isocyanate, sulfate, acid sulfate, phosphate, acid phosphate, carboxylate, dicarboxylate; R.sub.1, identical or different among them, represent a hydrogen atom, or an allyl group (CH.sub.2CHCH.sub.2); or are selected from alkyl groups C.sub.1-C.sub.20, preferably C.sub.1-C.sub.15, linear or branched, optionally halogenated, optionally substituted cycloalkyl groups; n is an integer ranging from 0 to 3; R.sub.2, identical or different among them, are selected from optionally substituted aryl groups; R.sub.3, identical or different among them, represent a hydrogen atom, or an allyl group (CH.sub.2CHCH.sub.2); or are selected from alkyl groups C.sub.1-C.sub.20, preferably C.sub.1-C.sub.15, linear or branched, optionally halogenated, optionally substituted cycloalkyl groups, optionally substituted aryl groups; R.sub.4 represents a group NR.sub.5 wherein R.sub.5 represents a hydrogen atom, or is selected from C.sub.1-C.sub.20 alkyl groups, preferably C.sub.1-C.sub.15, linear or branched; or R.sub.4 represents an alkylene group (CH.sub.2) p- wherein p represents an integer ranging from 1 to 5; provided that in the general formula (I), in case n is equal to 1 and R.sub.1 is methyl, R.sub.2 is different from phenyl.

Said phosphinic vanadium complex having general formula (I) or (II) can be advantageously used in a catalytic system for the (co)polymerization of conjugated dienes.

Method for the production of tetrakis(trihydrocarbylphosphane)palladium(0) in organic solvent, whereby 50 to 100% by weight of the organic solvent consist of at least one polar-aprotic solvent, characterised in that a) at least one palladium compound selected from the group consisting of palladium(II) compounds and palladium(IV) compounds that are soluble in the organic solvent is reacted with b) at least one base, selected from the group consisting of alkali metal hydroxides, alkali metal carbonates, alkali metal hydrogen carbonates, alkali metal-C.sub.1-C.sub.4-alcoholates, ammonium carbonate, ammonium hydrogen carbonate, alkaline earth metal hydroxides, alkaline earth metal carbonates, alkaline earth metal hydrogen carbonates, alkaline earth metal-C.sub.1-C.sub.4-alcoholates, and alkylamines with a total of 2 to 12 carbon atoms; c) at least one trihydrocarbylphosphane; and d) at least one organic reducing agent that is different from the remaining components that are used in the method.

Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.

Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.

A compound that includes a ligand L.sub.A of Formula I, Formula II, or Formula III, and the ligand L.sub.A is coordinated to a metal M.

##STR00001##

Ring A is a 5-membered, or 6-membered, aromatic ring, and Ring B a 5-membered, or 6-membered, carboxylic or heterocyclic ring.

Y.sup.1, Y.sup.2, and Y.sup.3 are independently selected from the group consisting of C, N, and B, and forms an aromatic BN ring; wherein one of Y.sup.1, Y.sup.2, and Y.sup.3 is C, one of Y.sup.1, Y.sup.2, and Y.sup.3 is N, and one of Y.sup.1, Y.sup.2, and Y.sup.3 is B, and the B and N are adjacent ring atoms; and Z.sup.1 and Z.sup.2 are independently selected from the group consisting of C and N. The compounds can be used as phosphorescent dopant emitters in OLEDs. An OLED that includes an organic layer that includes a compound with a ligand L.sub.A of Formula I, Formula II, or Formula III, and a consumer product that includes the OLED.